4d Molecular Therapeutics (FDMT) Stock
Gene therapy developer targeting rare diseases with engineered viruses. Here's the price, business snapshot, and what's worth knowing about 4d Molecular Therapeutics in November 2026.
4D Molecular Therapeutics (FDMT) is a clinical-stage biotechnology company developing targeted adeno-associated virus (AAV) gene therapies. The firm uses an engineered AAV platform — informed by directed evolution and design — to aim delivery to specific tissues such as the eye, central nervous system and liver, seeking treatments for rare genetic and metabolic disorders. As a research-led company with a market capitalisation around $525m, its value depends heavily on clinical trial outcomes, regulatory decisions and potential partnerships or licensing deals. Investors should expect volatility typical of small-cap biotech stocks: programmes can advance or fail, and further fundraising or dilution is possible. This is general educational information, not investment advice; consider your risk tolerance and time horizon and consult a professional before making decisions.
4d Molecular Therapeutics (FDMT) Stock Forecast
Analyst price target, next 12 months
$33.65
+188.1% vs today's $11.68
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering 4d Molecular Therapeutics have a consensus 12-month target of $33.65, above the current price of $11.68.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 22 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying 4D Molecular Therapeutics' stock with a target price of $33.65, indicating significant growth potential.
Financial Health
4D Molecular Therapeutics is performing well, showing strong revenue and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Engineered AAV platform
Directed-evolution and design aim to improve tissue targeting; clinical proof is required and outcomes can vary.
Catalysts to watch
Clinical readouts, regulatory milestones and partnership announcements can move the stock, but they also bring heightened volatility.
Niche disease focus
Concentrating on rare genetic and metabolic disorders may mean meaningful clinical impact if successful, though patient numbers and reimbursement can limit commercial scale.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.